BRAF and metastatic melanoma: A phase III trial (NCT01909453) compares the effectiveness and safety of LGX818 with MEK162 to vemurafenib and LGX818 monotherapy in patients with locally progressed, unresectable, or metastatic melanoma with the BRAF V600 mutation in two parts.